Consortium in CHF 23m series-C for Lunaphore

Existing investors including Redalpine Venture Partners, Occident and Alpana Ventures also participated in the financing round.

The fresh capital will be used for market and product expansion. This includes a US market entry, the ramp-up of activities in Europe and the development of new instruments.

Previous funding
In April 2015, Redalpine led a CHF 2m series-A round for Lunaphore alongside private investors. Subsequently, Redalpine invested again in a second funding round for the company. Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group also participated in the round, along with unnamed private investors.

Company
Established in 2014 and headquartered in Lausanne, Lunaphore is a life-sciences company developing equipment for cancer research and tissue diagnostics. The company has $6.5m in estimated annual revenues and employs 47 people, according to Owler.

People
PHC Holdings Corporation – Michael Kloss (CEO, president).
Lunaphore Technologies – Ata Tuna Ciftlik (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Venture
• Switzerland